Single peptide Vial strength 20 mg
Tesamorelin20 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
Tesamorelin, explained simply
A GHRH analogue clinically studied for visceral fat in a specific form of lipodystrophy.
Research area
Metabolism and hormones
How it works
Tesamorelin is a GHRH analogue that stimulates GH release and changes IGF-1 levels.
Why it matters
Clinical research examines visceral adipose tissue in a defined indication.
What has been observed
The approved indication concerns reduction of visceral fat in HIV-associated lipodystrophy.
Effects and points to consider
Results for that population and formulation do not automatically describe other goals or preparations.
01 / Vial strength 20 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 20 mg Tesamorelin |
|---|---|
| Final volume | 3 mL |
| Concentration | 6.67 mg/mL |
| One U-100 unit | 66.67 mcg in 0.01 mL |
Standard FDA-Approved Protocol (3.0 mL = ~6.67 mg/mL)
| Week | Daily Dose (mg / mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 1 mg / 1000 mcg | 15 units (0.15 mL) |
| Weeks 2–12+ | 2 mg / 2000 mcg | 30 units (0.30 mL) |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.